As an immunosuppressant, blocking mTOR (notably with the use of sirolimus) is linked to development of cancer (especially lymphoma and skin cancer), infections and other adverse events including hyperglycemia and dyslipidemia (236). This evidence concerns the gene MTOR and infection.